GLP-1 weight loss glossary
The words you meet while pricing a GLP-1: compounding, insurance, doses and how programs bill. Plain definitions, each with its source. For the prices themselves, see the monthly price index.
No insurance needed. Two cash programs to check.
Prices checked Nov 5, 2026.
- Check price →
- Check price →
- Check price →Eden's GLP-1 page, then an online assessment
5
503A pharmacy
A compounding pharmacy regulated under section 503A of the Federal Food, Drug and Cosmetic Act. 503A pharmacies prepare medications individually based on a prescription for a specific patient, under state board of pharmacy oversight rather than FDA new-drug approval. Most compounded GLP-1s in 2026 are prepared at 503A pharmacies.
Sources: Federal Food, Drug and Cosmetic Act, section 503A (Cornell LII); FDA, Human drug compounding; FDA, Compounding and the FDA: questions and answers. Read more about 503A pharmacy.
503B outsourcing facility
A larger compounding facility regulated under section 503B of the Federal Food, Drug and Cosmetic Act. Unlike a 503A pharmacy, a 503B facility registers with the FDA, can compound in bulk without a prescription for each patient, and must follow current good manufacturing practice (cGMP) with FDA inspections. The FDA publishes the list of registered facilities.
Sources: Federal Food, Drug and Cosmetic Act, section 503B (Cornell LII); FDA, Information for outsourcing facilities; FDA, Registered outsourcing facilities. Read more about 503B outsourcing facility.
A
Abbreviated New Drug Application (ANDA)
The FDA pathway by which generic drugs are approved. Generic semaglutide manufacturers must file ANDAs demonstrating bioequivalence with branded Wegovy. The first ANDAs for semaglutide were filed 2024-2025; first approvals expected late 2026.
ABOM (American Board of Obesity Medicine)
The American specialty board that certifies physicians in obesity medicine. ABOM-certified clinicians complete a fellowship or supervised training and pass a board exam. Form Health and Knownwell market themselves as employing ABOM-certified prescribers; most general telehealth programs do not.
Source: American Board of Obesity Medicine.
Active pharmaceutical ingredient (API)
The biologically active chemical in a medication. Semaglutide and tirzepatide are APIs. Compounded GLP-1s typically source API from FDA-registered manufacturers. The final compounded product is not FDA-approved as a drug product.
Sources: FDA, Medications containing semaglutide marketed for type 2 diabetes or weight loss; FDA, Concerns with unapproved GLP-1 drugs used for weight loss.
Adherence
How consistently a patient takes a medication as prescribed. Trial efficacy numbers assume high adherence; real-world adherence on GLP-1s runs lower because of dose-titration friction, side effects and supply gaps. Adherence below 80% reduces weight loss roughly proportionally.
Our definition, as used in our price checks.
All-in pricing
The total monthly cost a patient actually pays, including membership, medication, visits and lab fees, with no add-ons hidden behind a low headline price. Some programs bundle compounded GLP-1 into an all-in monthly fee; most programs unbundle medication and bill separately.
Our definition, as used in our price checks.
Appeal
A request asking an insurance plan to reverse a denial, such as a refused prior authorization. Plans must tell you how to appeal and by when. A letter from the prescriber with BMI, related conditions and earlier attempts is the usual core of a GLP-1 appeal.
Source: HealthCare.gov glossary, Appeal.
Asynchronous visit
A telehealth visit with no live call: you fill in an online form and a licensed clinician reviews it later and prescribes if you qualify. Some states require a live video visit for some prescriptions, which is one reason a program may not serve every state.
Source: FDA BeSafeRx, Locate a state-licensed online pharmacy.
B
Beyond-use date (BUD)
The date after which a compounded product should not be used, set by the compounder rather than tested like a manufacturer's expiry date. The FDA generally recommends using a multi-dose vial within 28 days of first use, because the risk of contamination rises after that, even when a compounder's label allows longer.
Source: FDA, Medications containing semaglutide marketed for type 2 diabetes or weight loss.
BMI (Body Mass Index)
Weight in kilograms divided by height in meters squared. Most insurance plans require BMI ≥30 for GLP-1 weight loss coverage, or BMI ≥27 with an obesity-related comorbidity. BMI is a population-level statistic and a poor individual diagnostic. It is the gate insurance plans use.
Our definition, as used in our price checks.
Branded drug
A medication marketed under a manufacturer's brand name, FDA-approved as a new drug and protected by patent. Wegovy (Novo Nordisk), Zepbound (Eli Lilly), Ozempic (Novo Nordisk) and Mounjaro (Eli Lilly) are branded drugs. Compounded versions are not branded drugs and are not FDA-approved.
Source: FDA, New drug application.
Bundled pricing
Membership fee and medication cost combined into a single monthly charge. Lower friction for cash-pay patients because the price doesn't change when you titrate up doses. Opposite: unbundled pricing, where membership is one charge and medication is a separate charge that scales with dose.
Our definition, as used in our price checks.
C
C-cell tumors / MTC
Medullary thyroid carcinoma. Animal studies on liraglutide showed thyroid C-cell tumors in rodents at higher-than-human doses; no human signal has been observed but a boxed warning is included on every GLP-1 label. Patients with a personal or family history of MTC or MEN2 syndrome should not take GLP-1s.
Sources: Wegovy label (DailyMed, NIH); Zepbound label (DailyMed, NIH).
Cardiometabolic
Relating to both cardiovascular disease and metabolic conditions (type 2 diabetes, dyslipidemia, hypertension, obesity). Insurance plans use cardiometabolic risk as a justification for GLP-1 prior-authorization approval at BMI 27 to 29.9. 9amHealth specifically targets cardiometabolic patients.
Our definition, as used in our price checks.
Cold chain
The refrigerated supply chain required for biologic medications. Branded GLP-1s ship between 2-8°C and must be refrigerated until first use, after which the pen is good at room temperature for up to 28 days. Patients traveling more than 24 hours need an insulated medication cooler with ice packs.
Sources: Wegovy label (DailyMed, NIH); Zepbound label (DailyMed, NIH).
Comorbidity
A medical condition co-occurring with another. For GLP-1 weight loss insurance coverage, common qualifying comorbidities include type 2 diabetes, hypertension, dyslipidemia (high cholesterol) and obstructive sleep apnea.
Our definition, as used in our price checks.
Compounded medication
A medication prepared at a pharmacy under prescription, customized for a patient or batch. Compounded medications are not FDA-approved as new drugs. The FDA does not review them for safety, effectiveness or quality, and a formulation, including the salt form, can differ from the approved drug it is prescribed in place of.
Sources: FDA, Compounding and the FDA: questions and answers; FDA, Concerns with unapproved GLP-1 drugs used for weight loss. Read more about Compounded medication.
Compounded tirzepatide
Tirzepatide made by a 503A or 503B compounding pharmacy rather than by Eli Lilly. The FDA does not approve it. Since tirzepatide left the shortage list, compounders cannot make plain copies of Zepbound or Mounjaro, so most sellers in 2026 sell a personalized formulation, often with vitamin B12 or another added ingredient.
Sources: FDA, Concerns with unapproved GLP-1 drugs used for weight loss; FDA drug shortages database; FDA guidance, Compounded drug products that are essentially copies of a commercially available drug product under section 503A.
Concentration (mg/mL)
How much drug is in each millilitre of a vial, printed on the label as mg/mL. It is the number that turns a syringe reading in units into a dose in milligrams. Compounded vials come in different strengths, and a refill can arrive at a new one.
Source: FDA, Medications containing semaglutide marketed for type 2 diabetes or weight loss.
CPA (Cost per acquisition)
The amount an affiliate or marketing channel pays for one converted customer. Weight loss program affiliate CPAs in 2026 range from ~$10 (Noom) to ~$300 (WeightWatchers Clinic on annual signups).
Our definition, as used in our price checks.
Custom formulation / personalized formulation
A compounded medication with an added ingredient, such as vitamin B12 or L-carnitine, alongside the GLP-1. Some 503A pharmacies moved to these versions after a drug left the FDA shortage list. It is a pharmacy-made version. Federal compounding rules permit it only in limited circumstances. Confirm the formulation with your prescriber.
Sources: FDA guidance, Compounded drug products that are essentially copies of a commercially available drug product under section 503A; Federal Food, Drug and Cosmetic Act, section 503A (Cornell LII).
Two cash programs to check.
No insurance needed.
Prices checked Nov 5, 2026.
- Check price →
- Check price →
- Check price →Eden's GLP-1 page, then an online assessment
D
Deductible
The amount you pay each year for covered care before the plan starts to pay. A GLP-1 on a plan with a high deductible can cost close to the full price until the deductible is met.
Sources: HealthCare.gov glossary, Deductible; HealthCare.gov glossary, Out-of-pocket costs.
Direct-to-consumer (DTC)
A distribution model where the manufacturer or program sells directly to patients without an intermediary. NovoCare and LillyDirect are DTC programs from Novo Nordisk and Eli Lilly that sell branded GLP-1s at reduced cash prices.
Our definition, as used in our price checks.
Dyslipidemia
Abnormal blood lipid levels (high LDL, low HDL, high triglycerides). One of the qualifying comorbidities for GLP-1 prior-authorization approval at BMI 27 to 29.9. Often documented in routine lipid panels at annual physicals.
Our definition, as used in our price checks.
E
Eli Lilly
American pharmaceutical company that manufactures Mounjaro and Zepbound (tirzepatide). LillyDirect is Lilly's direct-to-consumer cash-pay channel.
Our definition, as used in our price checks.
Essentially a copy
The FDA's term for a compounded drug that is the same as an FDA-approved drug on the market. A 503A pharmacy may not compound essentially a copy regularly or in large amounts unless the patient needs a change the prescriber documents, such as a different strength or an added ingredient. It is why compounded tirzepatide and semaglutide are now sold as personalized formulations.
Sources: FDA guidance, Compounded drug products that are essentially copies of a commercially available drug product under section 503A; Federal Food, Drug and Cosmetic Act, section 503A (Cornell LII). Read more about Essentially a copy.
Excipient
An inactive ingredient added to a medication for stability, absorption or shelf life. Brand Wegovy and a compounded semaglutide are formulated with different excipients. That is one reason a patient can tolerate one and not the other.
Our definition, as used in our price checks.
F
FDA approval
The Food and Drug Administration's process for clearing new drugs for sale. Wegovy was approved for chronic weight management in 2021. Compounded versions of approved drugs are not separately FDA-approved as drug products; they exist under separate compounding regulations.
Sources: FDA, New drug application; FDA, Compounding and the FDA: questions and answers.
FDA shortage list
The FDA's public list of drugs in official shortage. While a drug is on it, compounders have more room to make copies. Semaglutide was listed from 2022 until the FDA called the shortage over in February 2025; tirzepatide from late 2022 until October 2024 (confirmed that December). Both are off the list now.
Sources: FDA drug shortages database; FDA, Concerns with unapproved GLP-1 drugs used for weight loss.
Formulary
An insurance plan's list of covered drugs, organized by tier. Wegovy and Zepbound typically sit on Tier 3 or 4 with prior-authorization required. If a drug is not on the formulary at all, the plan does not cover it for any condition.
Sources: HealthCare.gov glossary, Formulary; HealthCare.gov glossary, Prescription drug coverage.
Foundayo
The brand name of orforglipron, Eli Lilly's once-daily oral GLP-1 tablet. The FDA approved it for chronic weight management on April 1, 2026.
Our definition, as used in our price checks.
FSA (Flexible Spending Account)
A tax-advantaged employer-sponsored account for medical expenses. Same eligibility as HSA for GLP-1 weight loss, but FSA balances generally don't roll over year-to-year.
Sources: HealthCare.gov glossary, Flexible spending account; IRS Publication 502, Medical and dental expenses.
G
Generic drug
A medication chemically identical to a branded drug, manufactured by a non-originator company under FDA approval after the originator's exclusivity has expired. The first generic semaglutide approvals are expected late 2026 to early 2027.
Sources: HealthCare.gov glossary, Generic drugs; FDA, Abbreviated new drug application.
GIP receptor
Glucose-dependent insulinotropic polypeptide receptor. Tirzepatide is a dual GLP-1 + GIP receptor agonist; semaglutide is GLP-1 only. The dual mechanism is the leading theory for tirzepatide's higher mean weight loss in registration trials.
Sources: MedlinePlus, Tirzepatide injection; Zepbound label (DailyMed, NIH).
GLP-1 (Glucagon-like peptide-1)
A hormone that slows gastric emptying, promotes satiety and stimulates insulin release. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and dual GLP-1/GIP agonists (tirzepatide) mimic this hormone for weight loss and diabetes treatment.
Sources: MedlinePlus, Semaglutide injection; Wegovy label (DailyMed, NIH).
Goal weight
The target weight where the active weight-loss phase ends and maintenance begins. It's the decision point: stay on the GLP-1 to hold the loss, or stop and accept a high chance of regain.
Our definition, as used in our price checks.
H
HSA (Health Savings Account)
A tax-advantaged account for medical expenses, paired with high-deductible insurance plans. GLP-1 weight loss medications and most weight-loss telehealth memberships are HSA-eligible expenses.
Sources: HealthCare.gov glossary, Health savings account; IRS Publication 502, Medical and dental expenses.
I
Insulin resistance
A metabolic state where cells respond less to insulin, common in obesity, prediabetes and PCOS. GLP-1 agonists improve insulin sensitivity independently of weight loss. That is part of why the class works for diabetes and PCOS in addition to obesity.
Our definition, as used in our price checks.
L
LegitScript
A private compliance certification organization that verifies legitimate online pharmacies and healthcare merchants. Google, Meta and Microsoft require LegitScript Healthcare Certification for GLP-1 advertising. Most major weight-loss telehealth programs carry it.
Source: LegitScript.
LillyDirect
Eli Lilly's direct-to-consumer cash-pay channel for Zepbound. Vial format is cheaper than pen format. As of 2026 single-vial Zepbound runs $299 to $699/month depending on dose tier, or $449 at 7.5mg and up with refills within 45 days. It undercuts most compounded tirzepatide pricing.
Our definition, as used in our price checks.
Liraglutide
An older GLP-1 receptor agonist marketed as Saxenda for weight loss and Victoza for diabetes. Less effective for weight loss than semaglutide and tirzepatide; mostly displaced by them.
Sources: Saxenda label (DailyMed, NIH); Victoza label (DailyMed, NIH).
List price
The price a manufacturer sets before rebates or discounts, also called wholesale acquisition cost. Few people pay it: insured patients pay a copay and cash patients usually pay a self-pay price. News reports of a drug costing over $1,000 a month are usually quoting list price.
Our definition, as used in our price checks.
Lock-in / commitment
A term in a subscription contract requiring the patient to remain enrolled for a defined period. A handful of the programs in our chart use 6-month or 12-month locks; most are month-to-month.
Our definition, as used in our price checks.
M
Maintenance dose
The dose a patient stays on long-term after reaching goal weight. Some patients maintain at the maximum dose; others step down to a lower dose. The data on step-down maintenance is thin; the practice is increasingly common but not formally trialed.
Sources: Wegovy label (DailyMed, NIH); Zepbound label (DailyMed, NIH). Read more about Maintenance dose.
Member reviews
A program's public Trustpilot rating (out of 5), mapped to a 0-10 score, published on the chart as "What members say" and one of GLP Chart's five scoring dimensions. Measures member satisfaction with the program, not clinical outcomes. Programs with no Trustpilot profile are labeled as such rather than scored on an invented number.
Our definition, as used in our price checks.
Membership fee
A monthly fee some telehealth programs charge for the clinician, messaging and refills, billed apart from the medication. A low medication price plus a membership can cost more than one all-in price. The chart adds both together.
Our definition, as used in our price checks.
Microdose protocol
A program's written plan for microdosing: a start below the labelled first dose and slower steps up. It is off-label. A few telehealth programs sell one; the protocol is the program's own, not an FDA-reviewed schedule.
Source: Wegovy label (DailyMed, NIH).
Microdosing
Taking a GLP-1 at a dose below the lowest labelled starting dose, for example less than 0.25 mg of semaglutide a week. It is off-label and has no large clinical trial behind it. People try it to stretch a supply or to cut side effects; how well it works at those doses is not established.
Sources: Wegovy label (DailyMed, NIH); FDA, Concerns with unapproved GLP-1 drugs used for weight loss. Read more about Microdosing.
Mounjaro
Eli Lilly's branded tirzepatide for type 2 diabetes. Often prescribed off-label for weight loss before Zepbound's 2023 approval; some programs still prescribe it off-label.
Source: Mounjaro label (DailyMed, NIH).
N
Novo Nordisk
Danish pharmaceutical company that manufactures Wegovy, Ozempic and Saxenda. Has pursued legal action against compounded semaglutide pharmacies and 2026 telehealth programs distributing compounded products.
Our definition, as used in our price checks.
NovoCare
Novo Nordisk's direct-to-consumer cash-pay program for Wegovy. Provides discounted cash prices for branded Wegovy without requiring insurance navigation.
Our definition, as used in our price checks.
O
Off-label prescribing
Prescribing a medication for a condition different from its FDA-approved indication. Ozempic is FDA-approved for diabetes but commonly prescribed off-label for weight loss. Mounjaro for weight loss before Zepbound's approval was also off-label.
Source: FDA, Compounding and the FDA: questions and answers.
Orforglipron
The active ingredient in Foundayo, Eli Lilly's oral GLP-1. It is a small molecule taken as a daily tablet, not an injected peptide. The FDA approved it for chronic weight management on April 1, 2026.
Source: FDA, The drug development process: clinical research.
Ozempic
Novo Nordisk's branded semaglutide injectable for type 2 diabetes (lower doses than Wegovy). Often prescribed off-label for weight loss when Wegovy is unavailable or uncovered by insurance.
Source: Ozempic label (DailyMed, NIH).
P
Patent cliff
The point at which a pharmaceutical patent expires and generic competition can enter the market. Semaglutide's primary patent expires in 2032 in the United States, after which ANDA generics will likely launch. Branded prices typically fall 70 to 90% within 18 months of patent expiry.
Our definition, as used in our price checks.
Peer-to-peer review
A phone call between the prescriber and the insurance plan's reviewing doctor about a denied request. It can overturn a prior authorization denial before a formal appeal is filed.
Sources: HealthCare.gov glossary, Appeal; HealthCare.gov glossary, Prior authorization.
Personalized advertising policy
Google Ads and Meta Ads policies restricting use of sensitive personal categories (including specific health conditions) for ad targeting. Practical effect: GLP-1 advertisers cannot target keywords containing drug names without LegitScript Healthcare Certification.
Our definition, as used in our price checks.
Pharmacy benefit manager (PBM)
The company that runs a health plan's drug benefit: it sets the formulary, applies prior authorization and step therapy, and negotiates rebates. CVS Caremark, Express Scripts and Optum Rx are the largest. A PBM's formulary decision is often why a GLP-1 is or is not covered.
Source: HealthCare.gov glossary, Formulary.
Prior authorization (PA)
An insurance plan's requirement that a prescription be reviewed before the plan agrees to pay for it. For GLP-1 weight loss, a PA usually asks for a BMI reading, any weight-related condition and sometimes proof of an earlier diet or drug attempt. Each plan sets its own criteria and timeline.
Sources: HealthCare.gov glossary, Prior authorization; HealthCare.gov glossary, Formulary. Read more about Prior authorization (PA).
R
Refill cadence
How often a patient orders new medication. Most telehealth programs default to monthly auto-shipment; some allow quarterly bulk shipping with pharmacy discretion. Cadence affects refrigerator storage planning.
Our definition, as used in our price checks.
S
Salt forms
Semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide in Wegovy and Ozempic. The FDA says salt forms should not be used to compound semaglutide and has warned sellers that use them. Ask a compounded program which form its pharmacy uses.
Sources: FDA, Medications containing semaglutide marketed for type 2 diabetes or weight loss; FDA, Concerns with unapproved GLP-1 drugs used for weight loss. Read more about Salt forms.
Savings card (copay card)
A manufacturer coupon that lowers what an insured patient pays at the pharmacy. The Wegovy and Zepbound savings cards need commercial insurance, and patients on Medicare, Medicaid or other government plans cannot use them. Without insurance, the manufacturers' own self-pay pharmacies (LillyDirect, NovoCare) are the cash route.
Source: Medicare.gov, Costs for Medicare drug coverage. Read more about Savings card (copay card).
Saxenda
Novo Nordisk's branded liraglutide for weight loss. Pre-dates and is less effective than Wegovy. Daily injection rather than weekly. Largely displaced by semaglutide and tirzepatide products.
Source: Saxenda label (DailyMed, NIH).
Self-pay (cash pay)
Paying for a prescription yourself instead of through insurance. Cash prices on the chart are self-pay prices. Some HSA and FSA cards can pay for a prescribed GLP-1; a cash payment usually does not count toward an insurance deductible.
Sources: IRS Publication 502, Medical and dental expenses; HealthCare.gov glossary, Deductible.
Semaglutide
The active GLP-1 receptor agonist molecule in Wegovy, Ozempic and Rybelsus. Most-prescribed GLP-1 in the world. Subject of compounded prescribing 2022-2026; FDA shortage status resolved February 2025.
Sources: MedlinePlus, Semaglutide injection; Wegovy label (DailyMed, NIH); Ozempic label (DailyMed, NIH).
Sequence
Original brand name of WeightWatchers Clinic. Acquired by WeightWatchers in 2023 and rebranded.
Our definition, as used in our price checks.
Single-dose vial
A vial that holds one dose and is thrown out after use. LillyDirect's Zepbound vials are single-dose, one vial a week. Compounded GLP-1 vials are usually multi-dose.
Source: Zepbound label (DailyMed, NIH).
Step therapy
An insurance plan's requirement that a patient try a cheaper drug first, and show it did not work or could not be tolerated, before the plan covers a more expensive one. For GLP-1 weight loss the first drug is often phentermine, naltrexone-bupropion or orlistat. The plan's own drug list (formulary) names the steps.
Sources: HealthCare.gov glossary, Formulary; HealthCare.gov glossary, Prior authorization. Read more about Step therapy.
Stockpiling
Buying and storing more medication than current use requires, usually as a hedge against supply disruption or price increase. Stockpiling compounded GLP-1 carries clinical risk (cold-chain breaks) and regulatory risk (some state pharmacy boards interpret it as resale). Stockpile no more than 90 days at a time.
Our definition, as used in our price checks.
T
Telehealth
Healthcare delivery via telecommunications technology, typically video or asynchronous messaging. All weight loss programs in our chart are primarily telehealth-delivered, with no in-person visits required for most patients.
Source: FDA BeSafeRx, Locate a state-licensed online pharmacy.
Tirzepatide
Eli Lilly's dual GLP-1/GIP receptor agonist molecule, in branded Mounjaro (diabetes) and Zepbound (weight loss). Generally produces greater weight loss than semaglutide in head-to-head trials.
Sources: MedlinePlus, Tirzepatide injection; Zepbound label (DailyMed, NIH); Mounjaro label (DailyMed, NIH).
Titration
Raising a medication dose in steps until it reaches the dose meant to be kept. The Wegovy pen label raises the dose every four weeks (0.25, 0.5, 1, 1.7, then 2.4 mg; a 7.2 mg Wegovy HD pen is a separate higher dose) and the Zepbound label adds 2.5 mg every four weeks, from 2.5 mg up to as much as 15 mg. The steps exist to limit stomach side effects.
Sources: Wegovy label (DailyMed, NIH); Zepbound label (DailyMed, NIH). Read more about Titration.
Trustpilot
An open online review platform. A program's public Trustpilot rating is the source of our fifth scoring dimension, published as "What members say", mapped to a 0-10 score.
Our definition, as used in our price checks.
U
U-100 syringe
The standard insulin syringe used for most compounded GLP-1 vials. U-100 means 100 units fill 1 mL. Syringes come in 0.3, 0.5 and 1 mL sizes, and some 0.3 mL syringes mark half units.
Source: FDA, Medications containing semaglutide marketed for type 2 diabetes or weight loss.
Units vs mg
A compounded GLP-1 vial is dosed by drawing units on a syringe, while the prescription is written in milligrams. On a U-100 syringe 100 units is 1 mL, so milligrams = units ÷ 100 × the vial's strength in mg/mL. 20 units is 0.5 mg in a 2.5 mg/mL vial but 1 mg in a 5 mg/mL vial. The FDA has reports of people hospitalized after dosing errors like this.
Source: FDA, Medications containing semaglutide marketed for type 2 diabetes or weight loss. Read more about Units vs mg.
V
Vial vs pen
A pen is prefilled and set to one dose per click; a vial holds liquid you draw up with a syringe. Branded Wegovy, Ozempic and Mounjaro come in pens. LillyDirect also sells Zepbound in single-dose vials, priced below the pen. Compounded programs ship multi-dose vials and syringes, so the dose depends on the vial's strength.
Sources: Zepbound label (DailyMed, NIH); FDA, Medications containing semaglutide marketed for type 2 diabetes or weight loss. Read more about Vial vs pen.
W
Wegovy
Novo Nordisk's branded semaglutide injection FDA-approved for chronic weight management. The first GLP-1 approved specifically for obesity. Sold at $1,300/mo retail or $149-$299/mo via NovoCare cash.
Source: Wegovy label (DailyMed, NIH).
WHO-GMP
World Health Organization Good Manufacturing Practice certification, a manufacturing quality standard recognized by regulators globally. The standard most non-FDA international generic manufacturers operate under.
Our definition, as used in our price checks.
Z
Zepbound
Eli Lilly's branded tirzepatide injection FDA-approved for chronic weight management. Sold at ~$1,100/mo retail or $299 to $699/mo via LillyDirect self-pay depending on dose ($449 at 7.5mg and up with 45-day refills), with single-dose vials and the multi-dose KwikPen priced the same.
Source: Zepbound label (DailyMed, NIH).